An exploratory, prospective phase II study to investigate progression-free survival, response and overall survival seen with pemetrexed/cisplatin and the role of thymidylate synthase expression.

Eli Lilly and Company Limited0 sites68 target enrollmentMarch 10, 2009

ConditionsAdvanced non-squamous non small cell lung cancer MedDRA version: 9.1Level: LLTClassification code 10025054Term: Lung cancer non-small cell stage IIIB MedDRA version: 9.1Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IV

DrugsAlimta

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Advanced non-squamous non small cell lung cancer
Sponsor: Eli Lilly and Company Limited
Enrollment: 68
Status: Active, not recruiting
Last Updated: 13 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

March 10, 2009

End Date

TBD

Last Updated

13 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Investigators

Sponsor

Eli Lilly and Company Limited

Eligibility Criteria

Inclusion Criteria

•The current Summary of Product Characteristics (SmPC) for pemetrexed will form the basis of patient selection. Patients are eligible to be included in the study only if they meet all of the following criteria:
•1\. Histological diagnosis of NSCLC which, in the opinion of the local pathologist and the treating physician, is non\-squamous cell histology. Pathology must be reviewed and confirmed prior to enrollment at the investigational site where the patient is entered. Patients will be enrolled based on local diagnosis; however, an independent centralised pathology review will be performed on all enrolled patients.
•2\. Adequate tumour biopsy specimen must be available for TS assessment. The local diagnostic slides, pathology report and tissue material must be available for central review.
•3\. Stage IIIB (with pleural effusion and/or positive supraclavicular lymph nodes) or Stage IV prior to induction therapy, as defined by the American Joint Committee on Cancer Staging Criteria for Lung Cancer, that is not amenable to curative therapy.
•4\. Have ECOG performance status of 0\-1\.
•5\. Have had no prior systemic treatment (for example chemotherapy, vaccination etc) for lung cancer, including previous adjuvant and neoadjuvant therapy.
•6\. Previous palliative radiotherapy to non\-target metastatic lesions is allowed to \<25% of the bone marrow (Cristy \& Eckerman, 1987\). This should have been limited and must not have included whole pelvis radiation. Patients must have recovered from the toxic effects of the treatment prior to study enrollment (except for alopecia). Prior radiotherapy must be completed 30 days before study enrollment. Lesions that have been radiated cannot be included as sites of measurable disease unless clear tumour progression has been documented in these lesions since the end of radiation therapy.
•7\. At least 1 unidimensionally measurable lesion meeting Response Evaluation Criteria in Solid Tumours (RECIST). The lesion should be at least 10mm in longest diameter by spiral computerized tomography (CT) scan, or at least 20mm by standard techniques. Tumour assessment at baseline should preferably be done with CT scan, although positron emission tomography (PET)\-CT scans are acceptable for inclusion. (CT scans should be used throughout the study for all further treatment assessments). Ultrasound may not be used for tumour measurements.
•8\. Estimated life expectancy of at least 12 weeks.
•9\. Patient compliance and geographic proximity that allow adequate follow up.

Exclusion Criteria

•Patients will be excluded from the study if they meet any of the following criteria:
•13\. Have small cell, large cell neuroendocrine or carcinoid histology, squamous cell carcinoma or tumours with a predominantly squamous component.
•14\. Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
•15\. Have a serious, uncontrolled medical condition that, in the opinion of the investigator, would compromise the patient’s ability to adhere to the protocol.
•16\. Have a second primary malignancy (except adequately treated non\-melanomatous skin cancer, or other cancer that is considered cured by surgical resection or radiation). Patients who had another malignancy in the past, but have been disease\-free for more than 5 years are eligible.
•17\. Have central nervous system (CNS) metastases (unless the patient has completed successful local therapy for CNS metastases and the investigator is convinced that the patient can take part). A screening CT scan or magnetic resonance imaging (MRI) before enrollment in the absence of a clinical suspicion of brain metastases is not required.
•18\. Are receiving concurrent administration of any other systemic antitumour therapy, including adjuvant chemotherapy.
•19\. Have clinically detectable (by physical examination) third\-space fluid collections, for example, ascites or pleural effusions that cannot be controlled by drainage or other procedures prior to study entry.
•20\. Have received a recent (within 30 days of enrollment) or are receiving concurrent yellow fever vaccination.
•21\. Are unable to interrupt aspirin or other nonsteroidal anti\-inflammatory agents, other than an aspirin dose \<\=1\.3 grams per day, for a 5\-day period (8\-day period for long\-acting agents, such as piroxicam).